display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/adv melanoma (mML)
mML - L2 - all populationmML - L2 - BRAF mutant
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone MDX010 Ipi vs gp100
Ipilimumab (10 mg/kg) CA184-004 Ascierto ...
ipilimumab plus gp100 MDX010 Ipi plus gp100 vs Ipi ... MDX010 Ipi plus gp100 vs gp100
ipilimumab plus SoC CA184-024
anti-PD-(L)1
nivolumab based treatment
nivolumab alone CheckMate 037
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab (10mg/kg) KEYNOTE-006 ... KEYNOTE-002 ...
pembrolizumab (10mg/kg) 2 weeks KEYNOTE-006 ...
pembrolizumab (2mg/kg) KEYNOTE-002 ...
pembrolizumab plus SoC KEYNOTE-022

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons